TNXP
Tonix Pharmaceuticals Holding Corp
7.70$
-4.6%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +10.9% | -12.4% | -48.1% | +35.1% | +71.5% | +18.4% | -2.9% | +34.7% | +9.8% | -6.9% | -1.5% | |
| – | +52.4% | -37.0% | -16.0% | +99.9% | +135.4% | +25.7% | -4.0% | +45.0% | +10.0% | -9.5% | -1.8% | |
| – | +260.8% | -71.7% | -41.0% | +579.3% | +249.9% | +33.3% | -4.8% | +51.6% | +9.3% | -10.7% | -5.0% | |
| – | – | – | -41.0% | +579.3% | +249.9% | +33.3% | -4.8% | +51.6% | +9.3% | -10.7% | -5.0% | |
| – | -100.0% | – | -27.3% | +20.2% | +97.0% | -38.9% | +63.1% | -55.8% | +180.3% | -9.6% | +33.8% | |
| – | +6.2% | -12.7% | -23.4% | -16.1% | +6.0% | -3.2% | -26.4% | -4.3% | +5.0% | -39.4% | +55.8% | |
| – | +0.0% | +0.0% | -100.0% | – | – | – | – | – | – | – | – | |
| – | -2.4% | -2.4% | -98.7% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +165.2% | -44.4% | +3.7% | -26.3% | +12.3% | -46.5% | +55.2% | +10.0% | +50.4% | -3.9% | +3.4% | |
| – | +6.5% | +8.4% | +7.6% | -31.1% | +20.6% | -33.7% | +56.9% | +10.3% | +46.6% | -3.9% | +3.8% | |
| – | – | – | +8.9% | -8.3% | -91.1% | -14.2% | -17.0% | -18.5% | -21.4% | +29.6% | +54.3% | |
| – | -51.5% | +75.8% | +56.5% | -62.2% | +15.5% | -7.8% | +85.6% | +9.7% | -5.0% | +18.9% | -6.2% | |
| – | – | -6.1% | -8.0% | -8.8% | -9.8% | – | – | – | – | – | – | |
| – | -12.7% | +2.5% | -61.1% | +76.3% | +88.1% | +29.3% | -6.9% | +37.6% | +6.1% | -7.3% | -2.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -49.4% | -31.0% | +5,072.3% | +52.1% | +39,979.9% | +161.9% | +23.6% | +21.8% | -4.6% | +61.0% | +21.4% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.